---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000059"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T16:17:31.010728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16

## Summary
- Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.
- Cash $758.5M at March 31, 2024, up from $239.6M Dec 31, after $350M offering and BioNTech financing.
- Obe-cel BLA under FDA review; PDUFA target action date Nov 16, 2024; MAA accepted by EMA.
- First two patients enrolled in SLE Phase 1 (CARLYSLE); initial data expected end of 2024.
- BioNTech strategic collaboration ($50M upfront, up to $582M milestones) and $200M private placement; Mike Bonney appointed Chairman.

## SEC filing metadata
- accession: 0001730463-24-000059
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/0001730463-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/autl-20240517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000059
- JSON: https://secwatch.observer/filing/0001730463-24-000059.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000059.txt

## Key facts
- Earnings Releases
  Autolus Therapeutics plc reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its operational and financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/0001730463-24-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.